+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ixempra 2018 U.S. Promotional Audit Report

  • ID: 4615886
  • Report
  • July 2019
  • Region: United States
  • 24 pages
  • MD Details
1 of 3

FEATURED COMPANIES

The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Ixempra through reportable promotional activity in 2018 and how does this compare to its peer set in the Breast Cancer market?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does R-Pharm and Kyowa's depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Radiation Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Ixempra throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Ixempra in 2018?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 500 paid interactions across 500 physicians made on behalf of Ixempra were carefully examined to support our analysis. In addition, interaction data from 15 peer products (i.e. Abraxane, Afinitor, Avastin, Fareston, Faslodex, Halaven, Herceptin, Ibrance, Kadcyla, Kisqali, Lynparza, Nerlynx, Perjeta, Talzenna, and Verzenio) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

Overview:
  • Introduction
  • Sunshine Act and Open Payments Data
  • Transfer of Value
  • Author's Platform
Ixempra - Peer Set:
  • Ixempra Peer Set Selection
Ixempra - Promotional Benchmarking:
  • Chart 1 Total Number of Physicians Reached by Specialty Type
  • Chart 2 Distribution of Physicians Reached by Specialty Type
  • Chart 3 Total Number of Payments by Type
  • Chart 4 Distribution of Payments by Type
  • Chart 5 Total Number of Payments / Week
  • Chart 6 Payment Value by Type
Ixempra - Physician Coverage by Geography:
  • Chart 7 Hematology/Oncology
  • Chart 8 Medical Oncology
  • Chart 9 Radiation Oncology
  • Chart 10 Internal Medicine
Ixempra - Meal Frequency:
  • Chart 11 Hematology/Oncology
  • Chart 12 Medical Oncology
  • Chart 13 Radiation Oncology
  • Chart 14 Internal Medicine
Ixempra - Most Engaged Physicians:
  • Table 1: Top Physicians (By Total Number of Meals) in 2018
  • Table 2: Top Speakers (By Total Number of Speaking Events) in 2018
About:
  • Background
  • Service Lines
  • Contact
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • R-Pharm
  • Kyowa
Note: Product cover images may vary from those shown
Adroll
adroll